biostudies-literatureChandwe KMedical Research CouncilWellcome Trust2910https://www.ebi.ac.uk/biostudies/studies/S-EPMC11024201biostudies-literatureUnknown15(1)Malnutrition underlies almost half of all child deaths globally. Severe Acute Malnutrition (SAM) carries unacceptable mortality, particularly if accompanied by infection or medical complications, including enteropathy. We evaluated four interventions for malnutrition enteropathy in a multi-centre phase II multi-arm trial in Zambia and Zimbabwe and completed in 2021. The purpose of this trial was to identify therapies which could be taken forward into phase III trials. Children of either sex were eligible for inclusion if aged 6-59 months and hospitalised with SAM (using WHO definitions: WLZ <-3, and/or MUAC <11.5 cm, and/or bilateral pedal oedema), with written, informed consent from the primary caregiver. We randomised 125 children hospitalised with complicated SAM to 14 days treatment wiNature communicationsMalnutrition enteropathy in Zambian and Zimbabwean children with severe acute malnutrition: A multi-arm randomized phase II trial.PMC11024201MR/P024033/1220566/Z/20/Z108065/Z/15/ZPlayford RJHill SAmadi BSonkwe HSauramba VVanBuskirk KChipunza MTawodzera GNgosa DMutasa BDzikiti AMurch SHChulu NMutasa KKelly PLanghaug LPrendergast AJChandwe KSturgeon JPMudzingwa SMakuyana RBwakura-Dangarembizi MKazhila LBesa EZyambo KSimunyola BZyambo MMudenda VMulenga CfalseMalnutrition enteropathy in Zambian and Zimbabwean children with severe acute malnutrition: A multi-arm randomized phase II trial.Malnutrition underlies almost half of all child deaths globally. Severe Acute Malnutrition (SAM) carries unacceptable mortality, particularly if accompanied by infection or medical complications, including enteropathy. We evaluated four interventions for malnutrition enteropathy in a multi-centre phase II multi-arm trial in Zambia and Zimbabwe and completed in 2021. The purpose of this trial was to identify therapies which could be taken forward into phase III trials. Children of either sex were eligible for inclusion if aged 6-59 months and hospitalised with SAM (using WHO definitions: WLZ <-3, and/or MUAC <11.5 cm, and/or bilateral pedal oedema), with written, informed consent from the primary caregiver. We randomised 125 children hospitalised with complicated SAM to 14 days treatment wi2024-01-01T00:00:00Z2024 Apr2026-06-01T10:48:38.737Z2026-04-08T11:37:33.043ZS-EPMC110242013863226210.1038/s41467-024-45528-0